Gemcitabine and Docetaxel for Hepatocellular Carcinoma
作者： Steven R. Alberts , Joel M. Reid , Bruce W. Morlan , Gist H. Farr , John K. Camoriano
DOI: 10.1097/COC.0B013E318219863B
关键词: Gemcitabine 、 Hepatocellular carcinoma 、 Medicine 、 Oncology 、 Deoxycytidine 、 Survival rate 、 Clinical trial 、 Docetaxel 、 Internal medicine 、 Cancer treatment 、 North central 、 Cancer research
摘要: ObjectivesFew effective options are available for the treatment of unresectable hepatocellular carcinoma (HCC). Several phase I trials suggest promising activity a combination gemcitabine and docetaxel.MethodsPatients with or metastatic HCC were treated docetaxel 40 mg/m2 (la
elsevier.com
lww.com
wkhealth.com参考文章(22)
René Bruno, Nicole Vivier, Christine Veyrat-Follet, Guy Montay, Gerald R. Rhodes, Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel Investigational New Drugs. ,vol. 19, pp. 163- 169 ,(2001) , 10.1023/A:1010687017717
Stefan Kubicka, Maja Katrin Tietze, Matthias Lorenz, Michael Manns, Karl Lenhard Rudolph, Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-gastroenterology. ,vol. 48, pp. 783- 789 ,(2001)
E. Niclas Jonsson, Mats O. Karlsson, Automated covariate model building within NONMEM. Pharmaceutical Research. ,vol. 15, pp. 1463- 1468 ,(1998) , 10.1023/A:1011970125687
Ching‐Lung Lai, Anna Suk‐Fong Lok, Pui‐Chee Wu, Gerald Chee‐Bunn Chan, Hsiang‐Ju Lin, None, Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. ,vol. 62, pp. 479- 483 ,(1988) , 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
Elio Sciarrino, Rosa Giovanna Simonetti, Salvatore Le Moli, Luigi Pagliaro, Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer. ,vol. 56, pp. 2751- 2755 ,(1985) , 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O
Pankaj Bhargava, John Marshall, Karen Fried, Marion Williams, Patricia Lefebvre, William Dahut, John Hanfelt, Edmund Gehan, Manuela Figuera, Michael Hawkins, Naiyer Rizvi, Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer Cancer Chemotherapy and Pharmacology. ,vol. 48, pp. 95- 103 ,(2001) , 10.1007/S002800100317
T.S. Yang, C.H. Wang, R.K. Hsieh, J.S. Chen, M.C. Fung, Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I–II trial Annals of Oncology. ,vol. 13, pp. 1771- 1778 ,(2002) , 10.1093/ANNONC/MDF303
Charles S. Fuchs, Jeffrey W. Clark, David P. Ryan, Mathew H. Kulke, Haesook Kim, Craig C. Earle, Michele Vincitore, Robert J. Mayer, Keith E. Stuart, A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma Cancer. ,vol. 94, pp. 3186- 3191 ,(2002) , 10.1002/CNCR.10607
Z Guan, Y Wang, S Maoleekoonpairoj, Z Chen, W S Kim, V Ratanatharathorn, W H H Reece, T W Kim, M Lehnert, Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. British Journal of Cancer. ,vol. 89, pp. 1865- 1869 ,(2003) , 10.1038/SJ.BJC.6601369
Tai-Shen Yang, Yung-Chang Lin, Jen-Shi Chen, Hung-Ming Wang, Chen-Hsu Wang, Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. ,vol. 89, pp. 750- 756 ,(2000) , 10.1002/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R